A Powerful New Tool for Early Identification of High Risk Patients Early
Intervention Can Help Prevent Disease Progression
SAN FRANCISCO, June 7 /PRNewswire/ -- Tethys Bioscience, Inc. announced today at the 68th Scientific Sessions of the American Diabetes Association (ADA) that it has expanded the availability of its novel PreDx(TM) Diabetes Risk Test, a first-of-its-kind predictive tool that delivers an accurate assessment of an individual's risk of developing Type 2 diabetes within the next five years. The test is performed exclusively by the Tethys Bioscience Clinical Laboratory on routinely collected blood samples.
The new blood test is designed to help physicians identify patients at highest risk of developing Type 2 diabetes so that they can promote lifestyle changes or initiate treatment plans to prevent or slow progression to Type 2 diabetes. Numerous studies have demonstrated that such interventions can reduce the incidence of new onset diabetes by 30-60%.
"There are a number of proven methods that clinicians can use to delay or prevent Type 2 diabetes in high-risk people," said Dr. Thomas Buchanan, Professor of Medicine at the University of Southern California Keck School of Medicine. "The problem has been the lack of an easy-to-use clinical test to identify the high-risk people. The PreDx Diabetes Risk Test solves that problem. For the first time, clinicians can order a single blood test to assess their patients' diabetes risk and identify those who are in greatest need of diabetes prevention. This is a real paradigm shift."
Using data generated from thousands of patients who were monitored for
up to 17 years, Tethys identified specific proteins and other biomarkers
that are most predictive of a person's progression to Type 2 diabetes.
Through comprehensive analysis of proteins and integration of multiple
risk-defining biomarkers, the company developed a sophisticated test
capable of stratifying at-risk in
|SOURCE Tethys Bioscience, Inc.|
Copyright©2008 PR Newswire.
All rights reserved